End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
18.61 CNY | -1.27% | +3.27% | +11.24% |
05-14 | Shanghai Pharmaceuticals Unit Gets Green Light to Market Cancer Drug | MT |
05-14 | Shanghai Pharmaceuticals Gets Regulatory Nod to Trial Tumor Drug | MT |
Sales 2024 * | 288B 39.9B 3,145B | Sales 2025 * | 317B 43.94B 3,463B | Capitalization | 62.4B 8.65B 682B |
---|---|---|---|---|---|
Net income 2024 * | 5.08B 704M 55.48B | Net income 2025 * | 5.84B 810M 63.81B | EV / Sales 2024 * | 0.26 x |
Net Debt 2024 * | 13.27B 1.84B 145B | Net Debt 2025 * | 19.41B 2.69B 212B | EV / Sales 2025 * | 0.26 x |
P/E ratio 2024 * |
12.8
x | P/E ratio 2025 * |
11.5
x | Employees | 48,164 |
Yield 2024 * |
3.02% | Yield 2025 * |
3.42% | Free-Float | 38.5% |
1 day | -1.27% | ||
1 week | +3.27% | ||
Current month | +3.85% | ||
1 month | +7.45% | ||
3 months | +5.74% | ||
6 months | +2.99% | ||
Current year | +11.24% |
Managers | Title | Age | Since |
---|---|---|---|
Yong Zhong Li
PSD | President | 54 | 26/06/19 |
Bo Shen
PSD | President | 51 | 04/06/13 |
Ye Lu
IRC | Investor Relations Contact | 35 | 31/12/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bo Shen
PSD | President | 51 | 04/06/13 |
Yong Zhong Li
PSD | President | 54 | 26/06/19 |
Manson Fok
BRD | Director/Board Member | 67 | 26/06/19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.86% | 2 M€ | -11.89% | - |
Date | Price | Change | Volume |
---|---|---|---|
15/05/24 | 18.61 | -1.27% | 13,402,800 |
14/05/24 | 18.85 | +3.23% | 28,550,150 |
13/05/24 | 18.26 | +0.83% | 15,223,420 |
10/05/24 | 18.11 | -0.33% | 9,684,412 |
09/05/24 | 18.17 | +0.83% | 9,539,018 |
End-of-day quote Shanghai S.E., May 14, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.24% | 8.64B | |
+19.13% | 71.69B | |
-3.66% | 23.65B | |
+8.80% | 9.01B | |
-18.91% | 8.15B | |
+16.00% | 5.33B | |
+17.83% | 4.35B | |
-2.11% | 4.1B | |
-1.72% | 3.94B | |
+27.53% | 3.81B |
- Stock Market
- Equities
- 601607 Stock